Advertisement

Clinical & Experimental Metastasis

, Volume 5, Issue 4, pp 277–287 | Cite as

Interferon-mediated enhancement of metastasis. Are MHC antigens involved?

  • Pier-Luigi Lollini
  • Carla De Giovanni
  • Brunella Del Re
  • Giordano Nicoletti
  • Giorgio Prodi
  • Patrizia Nanni
Article

The relationship between major histocompatibility complex (MHC) antigens and metastasis was investigated on B16 melanoma variants. B16 cell lines express low amounts of murine MHC (H-2) antigens. A high expression can be induced in line B16-A by in vitro treatment with immune interferon (IFN-gamma) or by in vivo transplant in allogeneic mice. The increase of H-2 antigens correlated with an enhancement of lung colonization in young syngeneic mice. The higher metastatic capacity of B16-A cells with induced high levels of H-2 antigens was observed also in adult mice and in young mice pretreated with cyclophosphamide. These results were confirmed investigating the behaviour of a mutant B16 clone (B78H1) which was selectively resistant to the H-2-inducing action of IFN-gamma: lung colonization ability was not increased by IFN pretreatment. The study of variants derived from individual B16-A lung colonies revealed a wide range of H-2 levels. Variants with a low expression had a low colonization ability; one out of two variants with a high H-2 expression also was poorly colonizing. IFN-gamma-mediated H-2 expression appeared to act as an enhancer, rather than a determinant of B16 metastatic capacity.

Keywords

Major Histocompatibility Complex Metastatic Capacity Colonization Ability Major Histocompatibility Complex Antigen Lung Colonization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Albino, A. P., Lloyd, K. O., Houghton, A. N., Oettgen, H. F., and Old, L. J., 1981, Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Journal of Experimental Medicine, 154, 1764–1778.Google Scholar
  2. [2]
    Bran, A. K., and Desmarais, C. L., 1983, Immunohistologic characterization of major histocompatibility antigens and inflammatory cellular infiltrate in human breast cancer. Journal of the National Cancer Institute, 71, 507–516.Google Scholar
  3. [3]
    Doyle, A., Martin, W. J., Funa, K., Gazdar, A., Carney, D., Martin, S. E., Linnoila, I., Cuttitta, F., Mulshine, J., Bunn, P., and Minna, J., 1985, Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. Journal of Experimental Medicine, 161, 1135–1151.Google Scholar
  4. [4]
    Eisenbach, L., Segal, S., and Feldman, M., 1983, MHC imbalance and metastatic spread in Lewis lung carcinoma. International Journal of Cancer, 32, 113–120.Google Scholar
  5. [5]
    Fidler, I. J., Gersten, D. M., and Budmen, M. B., 1976, Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity. Cancer Research, 36, 3160–3165.Google Scholar
  6. [6]
    Goodenow, R. S., Vogel, J. M., and Linsk, R. L., 1985, Histocompatibility antigens on murine tumors. Science, 230, 777–783.Google Scholar
  7. [7]
    Graf, L. H., Kaplan, P., and Silagi, S., 1984, Efficient DNA-mediated transfer of selectable genes and unselected sequences into differentiated and undifferentiated mouse melanoma clones. Somatic Cell and Molecular Genetics, 10, 139–151.Google Scholar
  8. [8]
    Greiner, J. W., HoranHand, P., Noguchi, P., Fisher, P. B., Petska, S., and Schlom, J., 1984, Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alfa-interferon treatment. Cancer Research, 44, 3208–3214.Google Scholar
  9. [9]
    Grönberg, A., Kiessling, R., Masucci, G., Guevara, L. A., Eriksson, E., and Klein, G., 1983, Gamma-interferon (IFN-gamma) produced during effector and target interactions renders target cells less susceptible to NK-cell-mediated lysis. International Journal of Cancer, 32, 609–616.Google Scholar
  10. [10]
    Hanna, N., and Burton, R. C., 1981, Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastasis in vivo. Journal of Immunology, 127, 1754–1758.Google Scholar
  11. [11]
    Katzav, S., De Baetselier, P., Tartakovsky, B., Feldman, M., and Segal, S., 1983, Alterations in major histocompatibility complex phenotypes of mouse cloned T10 sarcoma cells: association with shifts from nonmetastatic to metastatic cells. Journal of the National Cancer Institute, 71, 317–324.Google Scholar
  12. [12]
    LOllini, P.-L., Colombo, M. P., De Giovanni, C., Nicoletti, G., Parmiani, G., Prodi, G., and Nanni, P., 1985, In vivo reexpression of H-2 antigens in B16 melanoma cells. Experimental and Clinical Immunogenetics, 2, 14–23.Google Scholar
  13. [13]
    Maclean, G. D., Seehafer, J., Shaw, A. R. E., Kieran, M. W., and Longenecker, B. M., 1982, Antigeneic heterogeneity of human colorectal cancer cell lines analyzed by a panel of monoclonal antibodies. I. Heterogeneous expression of Ia-like and HLA-like antigenic determinants. Journal of the National Cancer Institute, 69, 357–364.Google Scholar
  14. [14]
    Nanni, P., Colombo, M. P., De Giovanni, C., Lollini, P.-L., Nicoletti, G., Parmiani, G., and Prodi, G., 1983, Impaired H-2 expression in B16 melanoma variants. Journal of Immunogenetics, 10, 361–370.Google Scholar
  15. [15]
    Nanni, P., De Giovanni, C., Lollini, P.-L., Nicoletti, G., and Prodi, G., 1983, TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clinical and Experimental Metastasis, 1, 373–380.Google Scholar
  16. [16]
    Natali, P. G., Viora, M., Nicotra, M. R., Giacomini, P., Bigotti, A., and Ferrone, S., 1983, Antigenic heterogeneity of skin tumors of nonmelanocyte origin: analysis with monoclonal antibodies to tumor-associated antigens and to histocompatibility antigens. Journal of the National Cancer Institute, 71, 439–447.Google Scholar
  17. [17]
    Nicolson, G. L., 1984, Tumor progression, oncogenes and the evolution of metastatic phenotypic diversity. Clinical and Experimental Metastasis, 2, 85–105.Google Scholar
  18. [18]
    Nishimura, J., Mitsui, K., Tanaka, Y., Yamamoto, R., Suhara, Y., and Ishitsuka, H., 1986, Restoration by recombinant interferon alpha A/D of host defense systems against tumor in immunosuppressed mice. Clinical and Experimental Metastasis, 4, 35–44.Google Scholar
  19. [19]
    Parmiani, G., Fossati, G., Taramelli, D., Anichini, A., Balsari, A., Gambacortipasserini, C., Sciorelli, G., and Cascinelli, N., 1985, Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells. Cancer and Metastasis Reviews, 4, 7–26.Google Scholar
  20. [20]
    Posts, G., and Fidler, I. J., 1980, The pathogenesis of cancer metastasis. Nature, 283, 139–146.Google Scholar
  21. [21]
    Posts, G., Doll, J., and Fidler, I. J., 1981, Interactions among clonal subpopulations affect stability of the metastatic phenotype in polyclonal populations of B16 melanoma cells. Proceedings of the National Academy of Sciences, U.S.A., 78, 6226–6230.Google Scholar
  22. [22]
    Ruiter, D. J.. Van Duinen, S. G., Bröcker, E. B., Schrier, P. I., Welvaart, K., and Ferrone, S., 1985, Low level of class I or high level of class II major histocompatibility complex antigens in metastatic melanoma is associated with a high grade of malignancy. Proceedings of the American Association for Cancer Research, 26, 315.Google Scholar
  23. [23]
    Schirrmacher, V., 1985, Cancer metastasis: experimental approaches, theoretical concepts, and impact for treatment strategies. Advances in Cancer Research, 43, 1–73.Google Scholar
  24. [24]
    Taniguchi, K., Karre, K., and Klein, G., 1985, Lung colonization and metastasis by disseminated B16 melanoma cells: H-2 associated control at the level of the host and the tumor cell. International Journal of Cancer, 36, 503–510.Google Scholar
  25. [25]
    Trinchieri, G., and Santoli, D., 1978, Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. Journal of Experimental Medicine, 147, 1314–1333.Google Scholar
  26. [26]
    Wallich, R., Bulbuc, N., Hämmerling, G. J., Katzav, S., Segal, S., and Feldman, M., 1985, Abrogation of metastatic properties of tumor cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature, 315, 301–305.Google Scholar
  27. [27]
    Wiltrout, R. H., Herberman, R. B., Zhang, S.-R., Chirigos, M. A., Ortaldo, J. R., Green, K. M.Jr., and Talmadge, J. E., 1985, Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver. Journal of Immunology, 134, 4267–4275.Google Scholar

Copyright information

© Taylor & Francis Ltd 1987

Authors and Affiliations

  • Pier-Luigi Lollini
    • 1
  • Carla De Giovanni
    • 1
  • Brunella Del Re
    • 1
  • Giordano Nicoletti
    • 1
  • Giorgio Prodi
    • 1
  • Patrizia Nanni
    • 1
  1. 1.Istituto di CancerologiaUniversità di BolognaBolognaItaly

Personalised recommendations